FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA

Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations

Jubilant Pharmova Limited subsidiary Jubilant Cadista Pharmaceuticals, solid oral formulations facility at Salisbury, Maryland, USA was inspected by the United States Food and Drug Administration (USFDA).

USFDA has issued five observations with no repeat observations. Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations within stipulated time.

Going forward the said facility is not expected to manufacture any products as it has closed manufacturing operations as was referenced in the previous disclosure dated April 18, 2024.